Cyclooxygenase-2 Inhibition for the Prophylaxis and Treatment of Preinvasive Breast Cancer in a Her-2/Neu Mouse Model

Tran‐Thanh, Danh; Buttars, Stephen; Wen, Yanxia; Wilson, C. M.; Done, Susan J.

doi:10.1158/1940-6207.capr-09-0181

Cited by 15 publications

(11 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of clinical testing of non-steroidal anti-inflammatory agents in dogs with cancer confirm the conclusions (Tran-Thanh et al, 2010) about the ability to prevent the growth of mammary tumours using a selective inhibitor of cyclooxygenase-2. The conclusions are based on research in which the animals were used as biological models, although information on the use of nonselective agents of this pharmacological group is controversial.…”

Section: Discussionsupporting

confidence: 66%

Pharmacological correction of the hemostasis system for the surgical treatment of bitches with tumours of the mammary gland

Bely

Rublenko

et al. 2018

Regul. Mech. Biosyst.

View full text Add to dashboard Cite

We carried out the clinical validation of pathogenetically substantiated protocols for the treatment of female dogs with tumour lesions of the mammary gland. The positive effect of corrective therapy was characterized by a decrease in the physiological level of fibrinogen: in benign tumours in 10 days, malignant – in 14 days against the background of its stable high level in control animals with malignant neoplasia. In the postoperative period in experimental animals, the functioning of the internal coagulation unit was restored, as evidenced by the normalization of the activated partial thromboplastin time for benign tumours by days 10–14, malignant – by 14 days. In control patients, these changes were detected only for benign neoplasms. Shifts of the external mechanism of blood coagulation in the experimental groups were eliminated in benign neoplasia cases in 10 days, malignant cases in 14 days against the background of severe disorders in this link in control patients throughout the observation period. The positive effect of complex treatment regimens is confirmed by the restoration of total fibrinolytic activity by days 10–14 due to the normalization in the same terms of the plasminogen activator and tissue plasminogen activator by days 3–7. In control animals, the total fibrinolytic activity was consistent with those of clinically healthy animals only for benign neoplasms. The balancing of coagulation and fibrinolytic mechanisms was accompanied by a decrease in the activity of proteolytic inhibitors: α2-macroglobulin in experimental groups with benign neoplasia by day 10, malignant – by days 10–14, and control – respectively, by days 3 and 14; α1-proteinase inhibitor in all groups by day 3. Concentration of nitric oxide after extirpation of benign tumors already at day 3 of the postoperative period in all groups corresponded to the indexes of clinically healthy dogs, with the removal of malignant tumours – in experimental animals at day 3, control – at day 14. The content of malondialdehyde and ceruloplasmin against the background of pharmacological correction was restored by days 10–14, whereas in control animals – only with benign neoplasms by day 14. Postoperative pharmacological correction of the hemostasis system can significantly improve the results of treatment in cancer patients.

show abstract

Section: Discussionsupporting

confidence: 66%

Pharmacological correction of the hemostasis system for the surgical treatment of bitches with tumours of the mammary gland

Bely

Rublenko

et al. 2018

Regul. Mech. Biosyst.

View full text Add to dashboard Cite

show abstract

“…Tumours were measured in length and width weekly to calculate the size. The tumor size progression (tumour size = 1/2 (length × width 2 )) and assessment of reduction in size were measured as described previously [27]. On 120th day of treatment, the rats were sacrificed after i.p injection of pentobarbital 100 mg/kg body weight.…”

Section: Methodsmentioning

confidence: 99%

Oral Administration of Tualang and Manuka Honeys Modulates Breast Cancer Progression in Sprague‐Dawley Rats Model

Ahmed

Sulaiman

Othman

2017

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Breast cancer has been recognized as the leading cause of death in women worldwide. Research has shown the importance of complementary and alternative therapies in cancer. In this study, we investigated the antitumoural therapeutic effects of Malaysian Tualang honey (TH) and Australian/New Zealand Manuka honey (MH) against breast cancer in rats. Thirty syngeneic virgin female Sprague-Dawley (SD) rats were induced by the carcinogen 1-methyl-1-nitrosourea (MNU) 80 mg/kg. The treatment started when first palpable tumour reached 10–12 mm in size by dividing rats into following groups: Group 0 (negative control); Group 1 (positive control); and Groups 2 and 3 which received 1.0 g/kg body weight/day of TH and MH, respectively, for 120 days. The data demonstrate that cancer masses in TH and MH treated groups showed a lower median tumour size, weight, and multiplicity compared with the nontreated positive control (p < 0.05). Treatment also showed a dramatic slower growth rate (up to 70.82%) compared with the nontreated control (0%) (p < 0.05). The antitumoural effect was mediated through modulation of tumour growth, tumour grading, estrogenic activity, and haematological parameters. Our findings demonstrate that systemic administration of TH and MH increases the susceptibility of expression of proapoptotic proteins (Apaf-1, Caspase-9, IFN-γ, IFNGR1, and p53) and decreases the expression of antiapoptotic proteins (TNF-α, COX-2, and Bcl-xL 1) in its mechanism of action. This highlights a potential novel role for TH and MH in alleviating breast cancer.

show abstract

“…The incidence (the percentage (%) of tumor-bearing rats in the group), the latency (the number of days taken for the rats to develop first tumor mass) and the size (in cm 3 ) of the tumor masses were recorded. Tumor size was measured using an established formula Tumor size = 1/2( length × width 2 ) [29]. On the 120th day of treatment, rats were subjected to necropsy after i.p injection of pentobarbital 100 mg/kg body weight.…”

Section: Methodsmentioning

confidence: 99%

The anti-cancer effects of Tualang honey in modulating breast carcinogenesis: an experimental animal study

Ahmed

Othman

2017

BMC Complement Altern Med

View full text Add to dashboard Cite

BackgroundHoney has been shown to have anti-cancer effects, but the mechanism behind these effects is not fully understood. We investigated the role of Malaysian jungle Tualang honey (TH) in modulating the hematological parameters, estrogen, estrogen receptors (ER1) and pro and anti-apoptotic proteins expression in induced breast cancer in rats.MethodsFifty nulliparous female Sprague–Dawley rats were used and grouped as follows: Group 0 (healthy normal rats control), Group 1 (negative control; untreated rats), Groups 2, 3 and 4 received daily doses of 0.2, 1.0 and 2.0 g/kg body weight of TH, respectively. The rats in groups 1, 2, 3, 4 were induced with 80 mg/kg of 1-methyl-1-nitrosourea (MNU). TH treatment in groups 2, 3 and 4 was started one week prior to tumor induction and continued for 120 days.ResultsThe TH-treated rats had tumors of different physical attributes compared to untreated negative control rats; the tumor progression (mean 75.3 days versus 51.5 days); the incidence (mean 76.6% versus 100%); the multiplicity (mean 2.5 versus 4 tumor masses per rat); the size of tumor mass (mean 0.41 cm versus 1.47 cm [p < 0.05]) and the weight of the tumor mass (mean 1.22 g versus 3.23 g; [p < 0.05]). Histological examinations revealed that cancers treated with TH were mainly of grades I and II compared with the non-treated control, in which the majority were of grade III (p < 0.05). TH treatment was found to modulate hematological parameters such as Hb, RBCs, PCV, MCV, RDW, MCHC, polymorphs and lymphocytes values. TH treatment groups were found to have a lower anti-apoptotic proteins (E2, ESR1 and Bcl-xL) expression and a higher pro-apoptotic proteins (Apaf-1 and Caspase-9) expression at serum and on cancer tissue level (p < 0.05).ConclusionTualang Honey alleviates breast carcinogenesis through modulation of hematologic, estrogenic and apoptotic activities in this experimental breast cancer animal model. Tualang Honey may be used as a natural ‘cancer-alleviating’ agent or as a supplement to chemotherapeutic agents.

show abstract

Cyclooxygenase-2 Inhibition for the Prophylaxis and Treatment of Preinvasive Breast Cancer in a Her-2/Neu Mouse Model

Cited by 15 publications

References 45 publications

Pharmacological correction of the hemostasis system for the surgical treatment of bitches with tumours of the mammary gland

Pharmacological correction of the hemostasis system for the surgical treatment of bitches with tumours of the mammary gland

Oral Administration of Tualang and Manuka Honeys Modulates Breast Cancer Progression in Sprague‐Dawley Rats Model

The anti-cancer effects of Tualang honey in modulating breast carcinogenesis: an experimental animal study

Contact Info

Product

Resources

About